4D PHARMA - Key Persons


Adrian Murray

Job Titles:
  • Intellectual Property Director
Adrian has an undergraduate degree in Medicinal Chemistry from the University of Warwick. Since graduating, Adrian qualified as a UK and European Patent and Trade Mark Attorney, as well as being awarded Chartered Chemist / Scientist status. Throughout his career, Adrian has advised all types of life sciences companies right through from start-ups to multinational giants on the development and implementation of IP protection and litigation strategies, advising on some of the sector's most high profile IP disputes. He has held the role of Senior Patent Counsel in Teva's in-house patent department and has also spent several years as a Partner in both a boutique patent and trade mark attorney firm, and, more recently, at international law firm Pinsent Masons.

Alex Stevenson

Job Titles:
  • Chief Scientific Officer
Alex began his career as a microbiologist, working in research for a number of years before joining an NYSE-quoted drug development company. He subsequently moved into pharmaceutical and healthcare investment and has fulfilled a number of board-level investment and operational management roles. He was a director and shareholder in Aquarius Equity from 2008, where he was responsible for identifying new investments and developing and implementing scientific strategies both pre and post-investment. These included Tissue Regenix Group plc, C4X Discovery Holdings plc and Brabant Pharma (subsequently sold to Zogenix, Inc.). Prior to joining Aquarius Equity, Alex worked for IP Group plc, where he specialised in life sciences investments identifying, developing and advising a number of companies in its portfolio, some of which went on to list on AIM. He joined IP Group following its acquisition of Techtran Group Limited in 2005. Alex is a co-founder of 4D pharma plc and has served as Chief Scientific Officer since 2014.

ALEXANDER JAMES STEVENSON

Job Titles:
  • DIRECTOR

Antonio Fernández

Job Titles:
  • General Manager
Antonio was the Chief Executive Officer at Instituto Biomar from 2002, leading a group of fermentation specialist and research scientists in microbiology and natural products chemistry. He received his PhD at Houston's M.D. Anderson Cancer Centre, conducting post-doctoral work in the Departments of Cell Biology and Molecular Pathology from the same institution. After this, Antonio worked in the Departments of Tumour Immunology, at the Dana-Farber Cancer Institute and then Surgical Research at the Children's Hospital, both associated with Harvard Medical School in Boston. He moved back to Spain in 2001, and worked at the research unit in Hospital de Leon from 2001 to 2002, when he joined Instituto Biomar. After the acquisition of Biomar´s production unit by 4D pharma in April 2016, Antonio took up the position of director at 4D pharma Leon.

AXEL GASTON GLASMACHER

Job Titles:
  • CONSULTANT
  • Director

Axel Glasmacher

Job Titles:
  • Non - Executive Director
Professor Dr. med. Axel Glasmacher was until recently Senior Vice President and Head of the Clinical Research and Development Hematology Oncology at Celgene, where he has worked in various global roles for more than ten years. His work at Celgene led to the approvals of Revlimid®, Idhifa® and Vidaza® (haematological cancers). He also worked on the PD-L1 inhibitor durvalumab. Prior to Celgene, Professor Glasmacher worked within the fields of haematology-oncology at the University Hospital in Bonn.

Christophe Carite

Job Titles:
  • Development Director
Christophe graduated in industrial pharmacy, and he started his industrial career as plant manager for Lallemand Bacteria Division, then occupied various positions in R&D and Marketing in B2B of Pharmaceuticals Ingredients. When presented with the challenge of producing Blautix™ he succeeded where others had previously failed and immediately understood the potential of this microorganism. Now, he is in charge of the pharmaceutical industrial development of all the 4D pipeline with the responsibility of all manufacturing sites.

David Norwood - Chairman

Job Titles:
  • Non - Executive Chairman
  • Member of the Committee
David has had a long career building a number of science, technology and investment companies. He is the founder of IP Group plc, one of the UK's leading technology commercialisation businesses, and a shareholder in the Company. Previously, he was chief executive of stockbroker Beeson Gregory (acquired by Evolution Group plc) after it acquired IndexIT Partnership, a technology advisory boutique he had founded in 1999. He was a founding shareholder of Evolution Group plc (acquired by Investec), and also co-founder of Ora Capital plc. He has been a founder and director of many UK technology companies including Oxford Nanopore Technologies Limited, Proximagen Limited, Synairgen plc, Ilika Technologies Limited, Oxford Catalysts and Plectrum Petroleum (acquired by Cairn Energy plc). He has also acted as seed investor and/or advisor to Wolfson Microelectronics Limited, Nanoco Technologies Limited, Tissue Regenix Group plc and Arc International (now part of Synopsys). He is also nonexecutive chairman of Oxford Pharmascience Group plc. He is also non-executive chairman of Abaco Capital plc and Genomics plc.

DAVID ROBERT NORWOOD

Job Titles:
  • DIRECTOR

Dr. Sandy Macrae

Job Titles:
  • Non - Executive Director
Dr. Sandy Macrae has over twenty years of experience in the pharmaceutical industry, with a combination of scientific, medical and commercial expertise. Dr. Macrae currently serves as President and Chief Executive Officer of Sangamo Therapeutics, Inc. ("Sangamo"; NASDAQ: SGMO), a leading genomic medicine company active in developing cell and gene therapies across a range of rare and large indications. Since Dr. Macrae joined Sangamo in 2016, the company has grown to have seven active clinical programmes, established multiple partnerships with major pharma groups, and seen its market capitalisation increase from around $350 million to approximately $1.35 billion today. Dr. Macrae has previously served as Global Medical Officer of Takeda Pharmaceuticals, overseeing medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences, and knowledge and informatics. Prior to that, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), and Vice President, Business Development. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology.

DUNCAN JOSEPH PEYTON

Job Titles:
  • DIRECTOR

Duncan Peyton - CEO

Job Titles:
  • Chief Executive Officer
Duncan has a proven track record in identifying, investing in and growing businesses within the pharmaceutical sector. He was the founder of Aquarius Equity, a specialist investor in businesses within the life sciences sector, which provided investors with access to innovative, high growth potential companies that delivered significant capital growth. Duncan started his career in a bio-science start-up business, which ultimately went on to list on the London Stock Exchange, subsequently qualified as a corporate finance lawyer with Addleshaw Goddard, then Addleshaw Booth & Co, and later joined 3i plc as an investment manager. Duncan founded Aquarius in 2005, which made founding investments into Nanoco Technologies Limited, Auralis Limited (subsequently sold to ViroPharma), Tissue Regenix Group plc, Brabant Pharma (subsequently sold to Zogenix, Inc and C4X Discovery plc. Duncan is a co-founder of 4D pharma plc and has served as Chief Executive Officer since 2014.

Ed Baracchini

Job Titles:
  • Non - Executive Director
Ed Baracchini has had a long and successful career in the pharmaceutical industry. He currently serves of the Board of Directors of INmune Bio, Inc. He was previously the Chief Business Officer at Xencor Inc. where he lead strategic alliances and licensing. During his time at Xencor he negotiated licence agreements with Novartis ($2.6 billion: immuno-oncology bispecific antibodies) , Novo Nordisk ($600 million: drug discovery collaboration), Amgen ($500 million: option and development agreement autoimmune disease antibody) among numerous others. Prior to that he served as SVP Business Development for Metabasis Therapeutics.

EDGARDO BARACCHINI

Job Titles:
  • DIRECTOR

Eileen O'Herlihy

Job Titles:
  • Project Manager
Eileen has a BSc in Plant Science and a PhD in Plant Biotechnology from University College Cork (UCC). She has worked as a post-doctoral researcher and as a manager on a range of projects both at national and EU level spanning plant and human health. In 2013, Eileen was project manager of ELDERMET, a nationally funded project that established diet-microbiota health interactions in over 500 elderly people. Following this post, she managed the Centre for Gerontology & Rehabilitation, UC,C where she was involved in initiatives focused on the elderly which also supported the European Innovation Partnership on Active and Healthy Ageing. She joined the APC Microbiome Institute (APC) in 2014 as EU Grants Manager where she engaged with stakeholders, built collaborations, inputted into draft work programmes and policy documents, and identified opportunities for microbiome research at national, EU and international level. She has over a decade of experience of working with industry partners in the capacity of research project manager and as a consultant. Eileen is very active in communicating science and creating an awareness through education and public engagement. She is also a member of the APC Microbiome Institute faculty. As Site Manager of 4D pharma Cork Limited, Eileen is responsible for the day-to-day running of the site including: management of clinical trials, administration, HR and liaising with other 4D sites and central management.

Imke Mulder

Job Titles:
  • Research Director
  • Research Director at 4D
Imke Mulder is the Research Director at 4D pharma Research Ltd in Aberdeen, Scotland, where she leads a multidisciplinary research group of 30 scientists. After completing her BSc and MSc in Biology at Wageningen University in the Netherlands, she moved to Aberdeen in 2001 to pursue her PhD studies at the Department of Zoology, working on the effects of dietary components on the gut immune system. Imke then carried out 8 years of post-doctoral work as a Research Fellow in the Gut Immunology Group at the Rowett Institute of Nutrition and Health (RINH) in Aberdeen. This work primarily focussed on interactions between the gut microbiota and the host immune system in different model organisms. Specific projects investigated how microbial composition and diversity influences early-life development of the mucosal immune system, and the cell-specific signalling pathways and effector molecules involved in driving health-promoting interactions of the gut microbiota. Imke moved to 4D pharma Research Ltd in 2014 where she leads the development of the MicroRx platform for the discovery of new live biotherapeutics.

John Weinberg

Job Titles:
  • Chief Medical Officer
John brings more than twenty years of big pharma and biotech experience to 4D Pharma. Most recently John served as Chief Operating Officer for Veloxis Pharmaceuticals A/S where he led the successful efforts to develop and launch the company's novel immunosuppressant agent, Envarsus. Prior to joining Veloxis, John served in roles of increasing responsibility across multiple therapeutic areas, including oncology, haematology and auto-immune diseases at Novartis, Enzon and Wyeth. John received his medical training at the University of the Witwatersrand School of Medicine, Johannesburg, South Africa, and his MBA degree from INSEAD in Fontainebleau, France.

LAURENCE SMITH DALE - Secretary

Job Titles:
  • Company Secretary

Laurie Dale - Chief Legal Officer, Secretary

Job Titles:
  • Company Secretary
  • General Counsel
  • General Counsel and Company Secretary of 4D
Laurie is General Counsel and Company Secretary of 4D pharma plc. In his role, he works closely with the Board and senior team, and supports all those within 4D in legal and regulatory compliance. He also co-ordinates the Group's external legal requirements. Prior to joining 4D pharma, Laurie was a corporate lawyer in private practice for over 20 years, holding senior positions with Addleshaw Goddard LLP and Schofield Sweeney LLP. He specialised in mergers and acquisitions and private and public fundraisings (advising corporates, funders and managers alike), and advised both private and quoted businesses generally on all aspects of corporate law. His clients were predominantly technology focussed and included Aquarius Equity Partners, Nanoco Technologies plc, Sanderson Group plc and C4X Discovery Holdings plc. He was also previously external counsel to 4D pharma, and advised it in relation to its IPO and initial fundraisings. He remains a qualified solicitor.

Stephen Dunbar - CFO

Job Titles:
  • Finance Director
With over 20 years of experience working with both private and listed business, Stephen has provided key financial and strategic advice since inception. Prior to joining 4D pharma plc, Stephen was Group Finance Director of Aquarius Equity Partners, a European healthcare fund. Stephen's role was key in not only the development of the funds, but also the financial stability of the group. At Aquarius, Stephen also played a key role in the development of the portfolio, working with management teams across companies such Nanoco Technologies, Tissue Regenix and Auralis, as well playing a more formal role as interim FD at Brabant Pharma. After qualifying as a Chartered Accountant with Tenon (now RSM), and working as Group FD for a local engineering company, Stephen founded an accountancy practice, Summ.it Assist LLP, which delivers outsourced tailor-made solutions covering financial, HR and IT solutions to SMEs and, since inception, has grown to over 30 staff across offices in Manchester and Mauritius. During this time Stephen has also acted as non-executive director for various SMEs and spent 18 months as interim FD for Touchstar Technologies during the successful reverse takeover of that business by Belgravium Technologies plc.

THOMAS ENGELEN - Founder

Job Titles:
  • DIRECTOR
  • Founder
  • Non - Executive Director
Thomas has been a founder and/or non-executive director of a number of UK life sciences companies including Colonis Pharma Limited, Warneford Partners Limited, Martindale Pharma Limited and Pneumagen Limited. Thomas has supported private equity and other investors in over 50 potential deal transactions, on targets in Europe and the USA, from cash constrained/chapter 11 to cash rich with enterprise value of up to $1 billion. Before this Thomas worked in life sciences for over 20 years in senior executive roles. Starting in 1987 at Akzo Nobel Pharma, he worked with hospital products, diagnostics and medical equipment as general manager for the Middle East and Africa. After this he led Rosemont Pharmaceuticals in Leeds in niche oral liquid medicines, followed by being president of Organon in Brazil. He was promoted to VP The Americas, and lastly to CMO at Organon, in charge of the global product portfolio, based in the USA. Returning to Europe he led Novartis Consumer Health in the UK. Thomas has also acted as non-executive chairman at Akcros Holdings Limited, Penlan Healthcare and Quantum Pharmaceutical.